Allergy Care Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Allergy Care Market is projected to experience substantial growth, rising from a valuation of USD 23.87 Billion in 2025 to USD 37.91 Billion by 2031, reflecting a CAGR of 8.01%. This sector encompasses a wide array of diagnostics, pharmaceutical interventions, and immunotherapies aimed at detecting and treating immune hypersensitivities caused by environmental, pharmaceutical, or dietary allergens.

Key factors propelling this expansion include the escalating prevalence of allergic conditions due to rapid urbanization, increasing pollution levels, and global changes in dietary patterns. Additionally, growing public awareness regarding the importance of early diagnosis and effective management is boosting the demand for both prescription and over-the-counter treatments. Data from the Asthma and Allergy Foundation of America highlights this burden, noting that in 2025, over 100 million people in the United States suffer from various allergies annually.

Despite strong market demand, high costs associated with advanced care present a major hurdle to industry expansion. The substantial expense of sophisticated diagnostic testing and long-duration immunotherapy regimens limits accessibility for a significant segment of the population, particularly within developing countries. This economic barrier effectively restricts the widespread adoption of comprehensive allergy solutions. Consequently, affordability remains a critical challenge that threatens to impede the anticipated growth trajectory of the global allergy care sector by excluding potential patients who cannot afford these premium medical interventions.

Market Drivers

Innovations in immunotherapy and the emergence of novel biologics are transforming the global allergy care landscape by moving clinical focus from temporary symptom management to long-term disease modification and desensitization. The recent debut of targeted biological therapies has offered revolutionary alternatives for patients with severe IgE-mediated food allergies who previously depended entirely on avoidance strategies. For instance, a February 2024 press release from Genentech regarding the FDA approval of Xolair reported that 67% of Phase III OUtMATCH study participants could safely ingest a single 600 mg dose of peanut protein without experiencing moderate to severe symptoms. This capacity to elevate reaction thresholds is fueling the uptake of high-value prescriptions, broadening the sector's commercial prospects as healthcare providers adopt these advanced regimens into standard protocols.

Furthermore, rapid urbanization and environmental pollution act as substantial market catalysts, with climate change intensifying allergen exposure and prolonging respiratory allergy seasons. Rising global temperatures are triggering earlier plant blooming and higher pollen concentrations, necessitating continuous medical treatment for a broader demographic. A CBS News report from April 2024 noted that data from the USA National Phenology Network showed spring conditions arriving up to 23 days earlier than usual in major cities like Detroit. This environmental shift is driving significant revenue increases for leading pharmaceutical companies as demand escalates; Sanofi reported in 2024 that second-quarter sales of its blockbuster immunology drug Dupixent rose by 29.2% to reach €3.30 billion.

Market Challenges

The prohibitive expense of specialized diagnostics and long-term immunotherapy remains a primary obstruction to the growth of the Global Allergy Care Market. While the incidence of hypersensitivities continues to climb, the steep costs attached to comprehensive care limit access for a vast portion of the global population. This financial hurdle is especially severe in developing countries and among uninsured groups, where individuals frequently opt for inexpensive, temporary symptomatic relief instead of necessary disease management. As a result, the industry faces difficulties in converting a high volume of potential patients into reliable revenue sources, which constrains the scalability of therapeutic offerings in price-sensitive markets.

The severity of this affordability gap is highlighted by statistical evidence regarding the financial burden on patients. According to reports from the European Academy of Allergy and Clinical Immunology, the average total cost per patient per year for allergic diseases was estimated at €1,329.55 in 2025. This substantial financial demand impedes the widespread uptake of sustained treatment plans. Consequently, these economic constraints directly hinder the industry's capacity to maximize its growth potential and achieve deeper market penetration across diverse global regions.

Market Trends

The Global Allergy Care Market is undergoing a significant transition toward Sublingual Immunotherapy (SLIT) as a favored alternative to conventional subcutaneous injections. This trend is defined by the growing uptake of standardized allergen tablets, which enable patients to self-administer disease-modifying therapies at home, effectively removing the logistical challenges associated with frequent clinic visits for shots. This move toward non-invasive care is broadening the addressable market for respiratory allergies by enhancing patient adherence and convenience. The commercial viability of this approach is evident in recent financial results; ALK-Abelló's 2024 annual report, released in February 2025, indicated that tablet sales rose by 24% to DKK 2.85 billion, fueled by increased volume and better pricing in European markets.

Simultaneously, the emergence of Digital Health and Tele-Allergy Platforms is transforming service delivery by closing the accessibility gap between specialists and patients. Providers are increasingly utilizing integrated digital ecosystems that leverage electronic consultations and remote triage to regulate patient flow, ensuring in-person resources are prioritized for complex, high-risk cases. This digital evolution enhances clinical efficiency and enables the management of allergic conditions without requiring physical attendance, thereby overcoming infrastructure limitations. The operational success of this shift is supported by clinical data; an April 2024 article in Frontiers in Allergy reported that 42.8% of electronic consultations originated from primary care in 2023 were resolved successfully without necessitating a face-to-face appointment.

Key Players Profiled in the Allergy Care Market

• ALK-Abello A/S
• AbbVie Inc.
• Allergy Therapeutics PLC
• Bausch Health Companies Inc.
• Alembic Pharmaceuticals Limited
• F. Hoffmann-La Roche Ltd.
• Nicox SA
• GlaxoSmithKline PLC
• Johnson & Johnson
• LETI Pharma, S.L.U

Report Scope

In this report, the Global Allergy Care Market has been segmented into the following categories:

Allergy Care Market, by Type:

• Eye Allergy
• Rhinitis
• Asthma
• Skin Allergy
• Food Allergies
• Other Allergies

Allergy Care Market, by Treatment:

• Anti-Allergy Drugs
• Immunotherapy

Allergy Care Market, by Distribution Channel:

• Hospital
• Online Pharmacies
• Retail Pharmacies
• Others

Allergy Care Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Allergy Care Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.